<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23024" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Herpes Virus Type 8</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rewane</surname>
            <given-names>Ayesan</given-names>
          </name>
          <aff>Rush University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayesan Rewane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23024.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The Human Herpesvirus-8 (HHV-8), also called Kaposi sarcoma Herpesvirus (KSHV), belongs to the family of DNA viruses Herpeseviridae. It causes Kaposi sarcoma (a vascular malignancy) and B cell lymphoproliferative diseases such as primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD). The likelihood of HHV-8-associated malignancies is significantly higher amongst individuals living with HIV. This activity reviews the evaluation and treatment of abdominal human herpesvirus-8 and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the disease conditions caused by human herpesvirus 8 (HHV-8).</p></list-item><list-item><p>Describe the epidemiology of human herpesvirus 8 (HHV-8).</p></list-item><list-item><p>Summarize the life cycle of human herpesvirus 8 (HHV-8).</p></list-item><list-item><p>Explain the current treatment options for Kaposi sarcoma by an interprofessional team.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23024&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23024">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23024.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Viruses are known to cause up to 20% of all human cancers. The Human Herpesvirus-8 (HHV-8), also called Kaposi sarcoma Herpesvirus (KSHV) and&#x000a0;Epstein-Barr virus (EBV/ HHV4) both belong to the family of DNA viruses Herpeseviridae. They are the only two members of the Herpes virus known to cause human cancers. EBV is known to cause Burkitt lymphoma. Other oncogenic viruses include the Human Papillomavirus (HPV), Hepatitis B (HBV), Human T-cell lymphotropic virus-1 (HTLV-1).<xref ref-type="bibr" rid="article-23024.r1">[1]</xref>&#x000a0;In 1994, the HHV- 8 was isolated as the cause of the skin malignancy Kaposi sarcoma (KS). Since the discovery, several prevalence studies have shown a unique pattern of the geographical distribution of this virus with no established explanation for this pattern.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r3">[3]</xref></p>
      </sec>
      <sec id="article-23024.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>HHV-8-Associated Tumors</bold>
</p>
        <p>The HHV-8 or KSHV is a double-stranded DNA virus subclassified as gammaherpesviruses. The gammaherpesviruses are a lymphotropic virus that undergoes lytic replication in epithelial cells such as skin, blood vessels, and organs. These viruses can establish latency in their host cells for a lifetime. The HHV-8 goes into a latency period in the B-lymphocytic cells and vascular endothelium. It intermittently undergoes a period of lytic replication, especially in favorable conditions like immunodeficiency, malnutrition, solid organ transplant, and so on. It causes Kaposi sarcoma (a vascular malignancy) and B cell lymphoproliferative diseases such as primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD). The likelihood of HHV-8-associated malignancies is significantly higher amongst individuals living with HIV; however, these malignancies can occur without HIV coinfection.&#x000a0;In rare cases where KS is diagnosed in non-AIDS patients, it is usually in elderly Mediterranean men or iatrogenic immunosuppression, including the transplant population.<xref ref-type="bibr" rid="article-23024.r1">[1]</xref><xref ref-type="bibr" rid="article-23024.r4">[4]</xref><xref ref-type="bibr" rid="article-23024.r5">[5]</xref><xref ref-type="bibr" rid="article-23024.r6">[6]</xref>&#x000a0;</p>
        <p><bold>Kaposi Sarcoma (KS)</bold>Moritz Kaposi, the dermatologist, first discovered the disease in 1872 among elderly European men. KS is typically regarded as an AIDS-defining condition, HHV-8 is the cause of approximately 95% of all cases of KS, regardless of the HIV/AIDS status. KS is a type of malignancy that affects the lymphovascular system and presents as pigmented skin lesions. There are four epidemiological forms of KS categorized as endemic KS, classic KS, and AIDS-associated KS and iatrogenic KS.<xref ref-type="bibr" rid="article-23024.r1">[1]</xref><xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r5">[5]</xref></p>
        <p>Classic or sporadic KS &#x02013; This form of KS is commonly seen in elderly Jewish and Mediterranean, Eastern European HIV-negative men, and clinically less aggressive. The classic KS typically presents as an upper and lower limb skin lesion, sparing the lymph nodes and visceral. Iatrogenic KS &#x02013; KS in organ transplantation, this is relatively less aggressive and presents with lymphadenopathy and visceral involvement. Epidemic or AIDS-associated&#x000a0;KS&#x000a0;&#x02013;&#x000a0;This is the most common and clinically aggressive form. Endemic KS&#x000a0;&#x02013;&#x000a0;KS in Africa and highly aggressive KS in adults, lymphadenopathy in children.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r5">[5]</xref><xref ref-type="bibr" rid="article-23024.r7">[7]</xref></p>
        <p><bold>Primary Effusion Lymphomas (PELs)</bold>PELs are rare lymphomatous effusions, also known as body cavity-based lymphoma (BCBL), and commonly associated with AIDS. It rarely occurs in individuals without HIV and is characterized as non-Hodgkin lymphoma.&#x000a0;This disease is unique because it occurs as an effusion in the pleural, pericardial, or peritoneal cavities without the presence of a mass, although masses may occur in the lymph nodes, lungs, and gastrointestinal tract.<xref ref-type="bibr" rid="article-23024.r5">[5]</xref><xref ref-type="bibr" rid="article-23024.r8">[8]</xref></p>
        <p><bold>Multicentric Castleman Disease (MCD)</bold> MCD is a rare form of lymphoproliferative disorder, it has an estimated equal prevalence in both HIV/AIDS positive and negative patients. The virus can be isolated in almost all cases in the HIV infected population and about half the HIV negative patients.<xref ref-type="bibr" rid="article-23024.r8">[8]</xref>&#x000a0;The typical features of the disease are systemic symptoms like fever, chills, and generalized lymphadenopathy and can occur even in patients with fairly normal CD4 cell counts. The diagnosis requires a high level of suspicion as it can easily be missed for a bacterial infection. MCD should be managed promptly because it can rapidly progress to a sepsis-like syndrome. If left untreated, MCD can progress to large B cell lymphoma.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r9">[9]</xref></p>
      </sec>
      <sec id="article-23024.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>There are seven known subtypes of HHV-8/KSHV (A, B, C, D, E, F, and Z).<xref ref-type="bibr" rid="article-23024.r10">[10]</xref><xref ref-type="bibr" rid="article-23024.r11">[11]</xref>&#x000a0;The universal prevalence of KSHV is about 5% to 20%, and it is endemic in sub-Saharan Africa. It is more likely that the high prevalence in the endemic region may be due to transmission through saliva as the virus is high in adults as well as children in this region.<xref ref-type="bibr" rid="article-23024.r3">[3]</xref> It may also be probably due to the prevalence of malaria infection. The U.S. has the least prevalence, estimated to be less than 10%. It is two-three times more common in men than women globally, more common in men who have sex with men compared to heterosexual men, especially in the non-endemic regions. Women have the lowest prevalence of the virus among all sexual categories. It has not been firmly established to be a sexually transmitted infection. There is only very little chance that it is transmitted via blood products and perinatally.<xref ref-type="bibr" rid="article-23024.r1">[1]</xref><xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r3">[3]</xref>&#x000a0;It can be transmitted through body fluids, mainly saliva, and most infections are subclinical and can go unnoticed.<xref ref-type="bibr" rid="article-23024.r4">[4]</xref></p>
      </sec>
      <sec id="article-23024.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>KSHV is a large enveloped, linear double-stranded DNA virus belonging to the subfamily, gammaherpesvirus, genera-rhadinovirus. It has an icosahedral capsid, a tegument (containing proteins and RNAs). The DNA virus produces several proteins that enable the virus to evade the host&#x02019;s immunity, replicates in the nucleus, and produces its potential oncogenic effects. These proteins interact with the various metabolic pathways of the cell such as the nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase (PI3K), replication and transcription activator (RTA), Janus kinase/signal transducer, and activator of transcription (JAK/STAT) and mitogen-activated protein kinase (MAPK). The most expressed protein is Latency-associated nuclear antigen-1 (LANA), which is important for latency and oncogenesis. Also, Viral cyclin is known to inhibit the tumor suppressor genes (p53 and retinoblastoma (RB) prevent apoptosis by controlling the cell cycle.<xref ref-type="bibr" rid="article-23024.r1">[1]</xref><xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r5">[5]</xref><xref ref-type="bibr" rid="article-23024.r12">[12]</xref><xref ref-type="bibr" rid="article-23024.r13">[13]</xref>&#x000a0;</p>
        <p>Several other viral lytic proteins are significant in cancer formation to include the viral G protein-coupled receptor (vGPCR), K1, K15, and viral IL-6, are known to increase the activity of cellular growth factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). These play significant roles in angiogenesis and oncogenesis. The knowledge of these various pathogenic processes of KSHV has improved the production of medications to treat several of the HHV-8 related diseases and malignancies.<xref ref-type="bibr" rid="article-23024.r4">[4]</xref><xref ref-type="bibr" rid="article-23024.r13">[13]</xref></p>
        <p><bold>Major KSHV Proteins and Functions</bold>The HHV-8 has several viral products that are important for infecting, establish latency, and cancer formation, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Latency-associated nuclear antigen-1 (LANA) - which is the major latency antigen.</p>
          </list-item>
          <list-item>
            <p>Kaposins - these are latent proteins with A, B, and C subtypes, the B subtype is the most important for tumorigenesis.</p>
          </list-item>
          <list-item>
            <p>Rta protein (ORF50) - it is a major initiator of viral reactivation.</p>
          </list-item>
          <list-item>
            <p>Viral IL-6 (vIL-6) - a major blocker of interferon signaling by binding to gp130</p>
          </list-item>
          <list-item>
            <p>Viral cyclin (v-cyclin)</p>
          </list-item>
          <list-item>
            <p>Viral Fas ligand ICE inhibitory protein (v-FLIP)</p>
          </list-item>
          <list-item>
            <p>Viral IL-6 (vIL-6) - a protein&#x000a0;known to block interferon signaling by directly binding to gp130.<xref ref-type="bibr" rid="article-23024.r1">[1]</xref><xref ref-type="bibr" rid="article-23024.r3">[3]</xref><xref ref-type="bibr" rid="article-23024.r4">[4]</xref><xref ref-type="bibr" rid="article-23024.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23024.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Kaposi sarcoma: The gold standard of diagnosis is a skin biopsy for histopathology. The macular or patch, plaque, nodular KS lesions all vary in histology. However, the presence of spindle-shaped cells is confirmatory and is seen in all forms of KS. The typical characteristics of spindle cells are elongated cytoplasm and nuclei, which may have inclusions of hyaline or hemosiderin.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r10">[10]</xref></p>
        <p>Multicentric Castleman disease (MCD): The lymph node histology typically shows germinal center expansion and proliferation of vascular endothelium. The infected cells significantly express IL-6.<xref ref-type="bibr" rid="article-23024.r8">[8]</xref></p>
        <p>Primary effusion lymphomas (PELs): The typical PEL histological features are consistent with anaplastic large cell and large cell immunoblastic lymphomas and significantly express CD45.<xref ref-type="bibr" rid="article-23024.r8">[8]</xref></p>
      </sec>
      <sec id="article-23024.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common manifestation of Kaposi sarcoma is the skin lesion; however, in some cases, it can affect multiple organs and systems of the body. Hence the presentation depends on the system involved.<bold>Skin:</bold>&#x000a0;Lesions that are usually colored (red, brown, or purple) and have a variety of dermatological&#x000a0;presentations&#x000a0;described as a patch, plaque, or a nodule. Ulcerated skin lesions can be painful and, however, high risk of cellulitis, given the vascular obstruction that can also occur from the lesions. Edema is a common complication; lesions around the eye may cause periorbital and facial swelling as well as the destruction of vision in severe cases.<bold>Gastrointestinal:</bold> Intestinal lesions may be asymptomatic, cause abdominal discomfort, bloody stools, weight loss, constipation, and intestinal obstruction.<bold>Pulmonary:</bold> lesions will be associated with respiratory symptoms like cough, shortness of breath, and hemoptysis.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23024.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of HHV-8 associated malignancies is based on the clinical presentation and mainly tissue biopsy for histology. Biopsy of skin lesion KS and lymph note for MCD. Also, tumor marker immunofluorescence staining is often utilized, the KSHV &#x02013; LANA, which is often very specific for KS. Others include complete blood count, serum chemistry, and HIV testing, as well as pertinent imaging for complete diagnostic workup.<xref ref-type="bibr" rid="article-23024.r9">[9]</xref><xref ref-type="bibr" rid="article-23024.r10">[10]</xref></p>
      </sec>
      <sec id="article-23024.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>KS: The early initiation of antiretroviral therapy in AIDS-associated KS can lead to possible regression of the disease.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref>&#x000a0;In the treatment of KS, several factors are to be considered, which include the staging of the disease, immune status, and extent of disease involvement. Localized intralesional chemotherapy with vinblastine, surgeries, and radiotherapy are options for small lesions. The World Health Organization recommends the use of antiretroviral therapy in the treatment of mild or moderate Kaposi sarcoma. In severe cases, are a combination of antiretroviral therapy, and systemic chemotherapy is recommended. Commonly used for severe cases is paclitaxel or pegylated liposomal doxorubicin. The antiviral combination of ganciclovir/valganciclovir, foscarnet/cidofovir, and valacyclovir/famciclovir have been shown to treat HHV-8 associated diseases and may have the potential to prevent the formation of Kaposi sarcoma.<xref ref-type="bibr" rid="article-23024.r1">[1]</xref><xref ref-type="bibr" rid="article-23024.r2">[2]</xref><xref ref-type="bibr" rid="article-23024.r8">[8]</xref></p>
        <p>PEL: combination chemotherapy-based treatment includes CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and modified DA-EPOCH (etoposide, doxorubicin, vincristine, cyclophosphamide). Both have an overall survival rate of approximately 40% when used with combination antiretroviral therapy in HIV/AIDS patients.<xref ref-type="bibr" rid="article-23024.r9">[9]</xref>&#x000a0;Options for treatment in a non-AIDS patient include liposomal anthracycline, which may be combined with bortezomib and prednisone. Radiation therapy is an option for individuals who are unable to tolerate chemotherapy or have chemo-resistant PEL.<xref ref-type="bibr" rid="article-23024.r8">[8]</xref></p>
        <p>MCD: Generally, combination chemotherapy with (CHOP or CVAD) is indicated, especially for systemic symptoms. Other treatment modalities are surgical excision, radiation, and immunological agents such as steroids, rituximab (anti-CD20), atlizumab (anti- IL-6 antibody) can be used in the treatment of MCD. Rituximab can be used alone or in combination therapy.<xref ref-type="bibr" rid="article-23024.r8">[8]</xref><xref ref-type="bibr" rid="article-23024.r9">[9]</xref>&#x000a0;</p>
        <p>There are several medications in different stages of clinical trials that target the various stages of the pathogenesis of HHV-8 associated diseases. Some of these include the NF-&#x003ba;B inhibitor (berberine, cepharanthine, bortezomib), which targets various stages of the oncogenic process. Others include medications targeting interleukin-2, interleukin-6, mTOR, MAPK/RTK signaling pathways, and angiogenesis.<xref ref-type="bibr" rid="article-23024.r1">[1]</xref><xref ref-type="bibr" rid="article-23024.r4">[4]</xref><xref ref-type="bibr" rid="article-23024.r14">[14]</xref></p>
      </sec>
      <sec id="article-23024.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Chancroid</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Candidiasis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Herpes zoster</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HIV lymphadenitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hand foot and mouth disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Kaposi sarcoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Kaposi sarcoma inflammatory cytokine syndrome (KICS)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Syphilis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23024.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The optimal patient outcome for HHV-8-associated malignancies, especially Kaposi's sarcoma, involves a multidisciplinary approach. MCD and PEL may cause multisystemic disease in severe cases and may be complicated with HIV/AIDS as&#x000a0;well as other infections. Kaposi sarcoma&#x000a0;skin lesions can cause many psychological consequences, especially if located anywhere visible such as the face.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref>&#x000a0;</p>
        <p>Frequently, KS may be challenging to diagnose for pathologists because of its histologic similarity to a variety of malignancies. Also, the treatment can be challenging as well; most treatment goals are palliative and not curative. However, chemotherapy is optimal for quality of life improvement.<xref ref-type="bibr" rid="article-23024.r2">[2]</xref></p>
      </sec>
      <sec id="article-23024.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23024&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23024">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/herpes-virus-type-8/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23024">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23024/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23024">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23024.s13">
        <title>References</title>
        <ref id="article-23024.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mui</surname>
                <given-names>UN</given-names>
              </name>
              <name>
                <surname>Haley</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Viral Oncology: Molecular Biology and Pathogenesis.</article-title>
            <source>J Clin Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>29</day>
            <volume>6</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">29186062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cesarman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Damania</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Krown</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whitby</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Kaposi sarcoma.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2019</year>
            <month>Jan</month>
            <day>31</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <pub-id pub-id-type="pmid">30705286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Majerciak</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Towards Better Understanding of KSHV Life Cycle: from Transcription and Posttranscriptional Regulations to Pathogenesis.</article-title>
            <source>Virol Sin</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-161</page-range>
            <pub-id pub-id-type="pmid">31025296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dittmer</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Damania</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.</article-title>
            <source>J Clin Invest</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>126</volume>
            <issue>9</issue>
            <fpage>3165</fpage>
            <page-range>3165-75</page-range>
            <pub-id pub-id-type="pmid">27584730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jha</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The Role of Gammaherpesviruses in Cancer Pathogenesis.</article-title>
            <source>Pathogens</source>
            <year>2016</year>
            <month>Feb</month>
            <day>06</day>
            <volume>5</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">26861404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damania</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nz</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Immunodeficiencies that predispose to pathologies by human oncogenic &#x003b3;-herpesviruses.</article-title>
            <source>FEMS Microbiol Rev</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-192</page-range>
            <pub-id pub-id-type="pmid">30649299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purushothaman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Uppal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>KSHV-Mediated Angiogenesis in Tumor Progression.</article-title>
            <source>Viruses</source>
            <year>2016</year>
            <month>Jul</month>
            <day>20</day>
            <volume>8</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">27447661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Damania</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis.</article-title>
            <source>Cancer Lett</source>
            <year>2010</year>
            <month>Mar</month>
            <day>28</day>
            <volume>289</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-50</page-range>
            <pub-id pub-id-type="pmid">19651473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Uldrick</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Yarchoan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated Kaposi sarcoma and related diseases.</article-title>
            <source>AIDS</source>
            <year>2017</year>
            <month>Sep</month>
            <day>10</day>
            <volume>31</volume>
            <issue>14</issue>
            <fpage>1903</fpage>
            <page-range>1903-1916</page-range>
            <pub-id pub-id-type="pmid">28609402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Dittmer</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Kaposi Sarcoma.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-539</page-range>
            <pub-id pub-id-type="pmid">28324233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tozetto-Mendoza</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Tateno</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sumita</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>MCA</given-names>
              </name>
              <name>
                <surname>Luna</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Pierrotti</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Braz-Silva</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Pannuti</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Genotypic distribution of HHV-8 in AIDS individuals without and with Kaposi sarcoma: Is genotype B associated with better prognosis of AIDS-KS?</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>95</volume>
            <issue>48</issue>
            <fpage>e5291</fpage>
            <pub-id pub-id-type="pmid">27902590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purushothaman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Uppal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Molecular biology of KSHV lytic reactivation.</article-title>
            <source>Viruses</source>
            <year>2015</year>
            <month>Jan</month>
            <day>14</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-53</page-range>
            <pub-id pub-id-type="pmid">25594835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mesri</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Cesarman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boshoff</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Kaposi's sarcoma and its associated herpesvirus.</article-title>
            <source>Nat Rev Cancer</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>707</fpage>
            <page-range>707-19</page-range>
            <pub-id pub-id-type="pmid">20865011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23024.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zoubeidi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aydi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Daoud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rachdi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Koubaa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jouini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baili</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Debbiche</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ben Dhaou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boussema</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Kaposi's Sarcoma Presenting as Lymphadenopathy in an Immunocompetent Patient.</article-title>
            <source>Eur J Case Rep Intern Med</source>
            <year>2016</year>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>000493</fpage>
            <pub-id pub-id-type="pmid">30755897</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
